Infectious Disease, Immunity & Inflammation

  • Image - How new hepatitis C drugs could tackle liver cancer, too

    How new hepatitis C drugs could tackle liver cancer, too

    Monday, 06 March 2017

      Wider availability of newer hepatitis C drugs may not only lead to fewer cases of this blood-borne disease, but may also slow the rise in related liver cancer.   But these so-called direct-acting antiviral drugs have not been widely available in Australia or overseas for long enough for us to...

  • Image - Latest research shows Australia on track to cure hep C

    Latest research shows Australia on track to cure hep c

    Tuesday, 21 February 2017

    Sydney, Australia – 21 February 2017: More Australians were treated for their hepatitis C infection in the first year new generation hepatitis C regimens were made available on the Pharmaceutical Benefits Schemes than in the past decade, according to a new report released today by the Kirby...

  • Image - Latest research shows Australia on track to cure hepatitis C

    Latest research shows Australia on track to cure hepatitis C

    Tuesday, 21 February 2017

    More Australians have been treated for hepatitis C in the past 12 months than the last decade combined, following the listing of a new generation therapy on the Pharmaceutical Benefits Scheme. A report released today by the Kirby Institute at UNSW Sydney found more than 30,000 Australians were...

  • Image - The Kirby Institute presented with key to the city

    The Kirby Institute presented with Key to the City

    Thursday, 16 February 2017

    The Lord Mayor of Sydney presents the Kirby Institute with key to the city, recognising 30 years of outstanding service to communities affected by HIV. The symbolic presentation is the highest honour a city can confer upon an individual or an organisation.   Sydney, Australia – 17...

  • Image - $12 million boost for HIV research at the Kirby Institute

    $12 million boost for HIV research at the Kirby Institute

    Thursday, 01 December 2016

    Sydney, Australia– UNSW’s Kirby Institute has been awarded a $12 million grant (AUD) from UNITAID to conduct aclinical trial to improve treatment options for people with HIV infection who experience treatment failure. TheD2EFTtrial is a multicentre, multinational, randomised trial in 610 people...

  • Image - Medical journal honours ‘Australia's fighter against HIV and discrimination’

    Medical journal honours ‘Australia's fighter against HIV and discrimination’

    Wednesday, 23 November 2016

    As it marks its 30th anniversary, the world-changing HIV research of UNSW’s Kirby Institute and its pioneering leader David Cooper has been acknowledged by the prestigious medical journal, The Lancet. Describing UNSW Scientia Professor Cooper as ‘Australia's fighter against HIV and discrimination...